Abstract
Proteases constitute one of the primary targets in drug discovery. In the present review, we focus on extracellular proteases (ECPs) because of their differential expression in many pathophysiological processes, including cancer, cardiovascular conditions, and inflammatory, pulmonary, and periodontal diseases. Many new ECP inhibitors are currently under clinical investigation and a significant increase in new therapies based on protease inhibition can be expected in the coming years. In addition to directly blocking the activity of a targeted protease, one can take advantage of differential expression in disease states to selectively deliver therapeutic or imaging agents. Recent studies in targeted drug development for the metalloproteases (matrix metalloproteinases, adamalysins, pappalysins, neprilysin, angiotensin-converting enzyme, metallocarboxypeptidases, and glutamate carboxypeptidase II), serine proteases (elastase, coagulation factors, tissue/urokinase plasminogen activator system, kallikreins, tryptase, dipeptidyl peptidase IV) and cysteine proteases (cathepsin B) are discussed herein.
Keywords: Drug targets, extracellular proteases, metalloproteases, serine proteases, cysteine proteases, protease inhibitors
Current Protein & Peptide Science
Title: Extracellular Proteases as Targets for Drug Development
Volume: 10 Issue: 4
Author(s): Mare Cudic and Gregg B. Fields
Affiliation:
Keywords: Drug targets, extracellular proteases, metalloproteases, serine proteases, cysteine proteases, protease inhibitors
Abstract: Proteases constitute one of the primary targets in drug discovery. In the present review, we focus on extracellular proteases (ECPs) because of their differential expression in many pathophysiological processes, including cancer, cardiovascular conditions, and inflammatory, pulmonary, and periodontal diseases. Many new ECP inhibitors are currently under clinical investigation and a significant increase in new therapies based on protease inhibition can be expected in the coming years. In addition to directly blocking the activity of a targeted protease, one can take advantage of differential expression in disease states to selectively deliver therapeutic or imaging agents. Recent studies in targeted drug development for the metalloproteases (matrix metalloproteinases, adamalysins, pappalysins, neprilysin, angiotensin-converting enzyme, metallocarboxypeptidases, and glutamate carboxypeptidase II), serine proteases (elastase, coagulation factors, tissue/urokinase plasminogen activator system, kallikreins, tryptase, dipeptidyl peptidase IV) and cysteine proteases (cathepsin B) are discussed herein.
Export Options
About this article
Cite this article as:
Cudic Mare and Fields B. Gregg, Extracellular Proteases as Targets for Drug Development, Current Protein & Peptide Science 2009; 10 (4) . https://dx.doi.org/10.2174/138920309788922207
DOI https://dx.doi.org/10.2174/138920309788922207 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Stem Cell-Based Therapies and Immunomodulatory Approaches in Newly Diagnosed Type 1 Diabetes
Current Stem Cell Research & Therapy Oral Submucous Fibrosis as an Overhealing Wound: Implications in Malignant Transformation
Recent Patents on Anti-Cancer Drug Discovery Clinical Application of Chitosan in Dental Specialities
Mini-Reviews in Medicinal Chemistry Editorial The Role of Mesenchymal Stem Cells in Bone Regeneration: Underlying Mechanisms and Systemic Regulatory Factors
Current Stem Cell Research & Therapy Comparative Account of Quality Management and Regulatory Aspects of Products with Health Claims: Existing Approaches and Future Challenges for Probiotics and Herbal Products
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Role of Electrospinning in the Emerging Field of Nanomedicine
Current Pharmaceutical Design Investigation of Methylene Blue Release from Functional Polymeric Systems Using Dielectric Analysis
Current Drug Delivery Oral Hygiene and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Selective Matrix Metalloproteinase Inhibitors for Cancer
Current Medicinal Chemistry MicroRNA in Implant Dentistry: From Basic Science to Clinical Application
MicroRNA Natural Bioactive Compounds Loaded Eggshell Membrane from Waste Food Industry: Preparation and Characterization
Current Nutraceuticals Oral Candidosis in HIV-Infected Patients
Current HIV Research Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Drug in Adhesive Transdermal Formulation of Valsartan and Nifedipine: Pharmacokinetics and Pharmacodynamics in Rats
Current Drug Therapy